Collen D, de Cock F, Cambiaso C L, Masson P
Eur J Clin Invest. 1977 Feb;7(1):21-6. doi: 10.1111/j.1365-2362.1977.tb01565.x.
An antiserum was raised in rabbits against human plasmin-antiplasmin complex and rendered specific for neoantigens of this complex by absorption with purified plasminogen and plasma. Polystyrene particles were coated with the specific antibodies and used in an agglutination test for the determination of plasmin-antiplasmin complex in the plasma from various patients. Purified plasmin-antiplasma complex at a concentration of 0.1-0.2 mg/l was found to cause a clear agglutination of the particles. Activation of fresh human plasma with urokinase caused progressive generation of agglutinating activity up to a plasma dilution of 1/480. Intravenous infusion of streptokinase into patients resulted in an increase of the plasmin-antiplasmin titre of at least 1/240. Sera from patients with rheumatoid factor also agglutinated the particles but this activity could be removed by absorbing rheumatoid factor on insolubilized human IgG. Out of 101 male and twenty-three female control subjects, only three men had a plasmin-antiplasmin titre above 1/16. Of 230 hospitalized patients, plasmin-antiplasmin titres of 1/40 or more were detected in twenty-five patients. Most of these patients had diseases which are frequently associated with in vivo coagulation or fibrinolysis, but among them there was only one who showed diffuse intravascular coagulation detectable by classical methods. In the absence of an increased plasmin-antiplasmin titre none of the haemostasis analyses were indicative of in vivo coagulation or fibrinolysis. Seven out of eight patients with diffuse intravascular coagulation of various origin had plasmin-antiplasmin titres of 1/80 or 1/160. Thus, the present latex agglutination test, owing to its simplicity and sensitivity, appears to be a practical routine screening test for detecting fibrinolytic activation in plasma.
用兔制备了抗人纤溶酶 - 抗纤溶酶复合物的抗血清，并通过用纯化的纤溶酶原和血浆吸收使其对该复合物的新抗原具有特异性。将聚苯乙烯颗粒用特异性抗体包被，并用于凝集试验，以测定来自不同患者血浆中的纤溶酶 - 抗纤溶酶复合物。发现浓度为0.1 - 0.2mg / l的纯化纤溶酶 - 抗血浆复合物可引起颗粒明显凝集。用尿激酶激活新鲜人血浆会导致凝集活性逐渐产生，直至血浆稀释至1/480。向患者静脉内输注链激酶会导致纤溶酶 - 抗纤溶酶滴度至少增加1/240。类风湿因子患者的血清也能凝集颗粒，但这种活性可通过将类风湿因子吸附在不溶性人IgG上来消除。在101名男性和23名女性对照受试者中，只有3名男性的纤溶酶 - 抗纤溶酶滴度高于1/16。在230名住院患者中，在25名患者中检测到纤溶酶 - 抗纤溶酶滴度为1/40或更高。这些患者中的大多数患有经常与体内凝血或纤维蛋白溶解相关的疾病，但其中只有一名患者通过经典方法显示出可检测到的弥漫性血管内凝血。在纤溶酶 - 抗纤溶酶滴度没有升高的情况下，没有一项止血分析表明存在体内凝血或纤维蛋白溶解。八名不同来源的弥漫性血管内凝血患者中有七名的纤溶酶 - 抗纤溶酶滴度为1/80或1/160。因此，目前的乳胶凝集试验由于其简单性和敏感性，似乎是一种检测血浆中纤维蛋白溶解激活的实用常规筛查试验。
